Henry Schein, a foundation devoted to promoting dental and medical health, has produced more than 27,000 comfort kits for people…
Articles by Patricia Inácio, PhD
GlaxoSmithKline’s investigational antibody-drug conjugate, belantamab mafodotin (GSK2857916), demonstrated a clinically meaningful overall response rate in hard-to-treat multiple…
People in Japan newly diagnosed with multiple myeloma and ineligible for a stem cell transplant can now use a combination…
The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow,…
A Phase 1 trial evaluating Teneobio’s bispecific antibody TNB-383B as a treatment for multiple myeloma has started dosing patients.
Allogene Therapeutics is launching the first clinical trial testing ALLO-715, its “off-the-shelf” CAR T-cell therapy, for people with…
A genomic rearrangement involving the immunoglobulin lambda (IgL) gene is predictive of resistance to immunomodulatory agents and poor outcomes among…
The U.S. Food and Drug Admnistration (FDA) has agreed to review Sanofi’s biologics license application (BLA) for its investigational antibody,…
A Phase 1 clinical trial is recruiting patients with hard-to treat or relapsed multiple myeloma to evaluate Mustang…
Cellectar Biosciences’ candidate CLR 131 received Fast Track designation by the U.S. Food and Drug Administration (FDA) for…